Klinische Neurophysiologie 2003; 34(3): 103-110
DOI: 10.1055/s-2003-42249
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Gammopathieassoziierte Polyneuropathien

Gammopathy-Associated PolyneuropathiesD.  Claus1
  • 1Klinik für Neurologie Klinische Neurophysiologie, Klinikum Darmstadt
Further Information

Publication History

Publication Date:
18 September 2003 (online)

Zusammenfassung

Polyneuropathien manifestieren sich bei M. Waldenström, Plasmozytom, Kryoglobulinämie, primärer Amyloidose sowie bei monoklonaler Gammopathie unbekannter Signifikanz (MGUS). Die Manifestationsform der paraproteinämischen Polyneuropathien ist meist symmetrisch. Die Neuropathien können sowohl vom demyelinisierenden, gemischten als auch vom axonalen Typ sein, ohne Unterschied zwischen IgG- oder IgM-MGUS. Die Differenzialdiagnostik gegenüber chronisch demyelinisierenden entzündlichen Polyneuropathien (CIDP) ist schwierig. Pathogenetisch kommen verschiedene Mechanismen infrage. Die richtige diagnostische Einordnung kann im Einzelfall eine frühe Diagnose proliferativer Prozesse (Plasmozytom, osteosklerotisches Myelom) sowie auch die erfolgreiche Therapie ermöglichen. Dabei spielt die Neurophysiologie eine wichtige Rolle.

Abstract

Peripheral neuropathies are seen in association with Waldenström's disease, plasmocytoma, cryoglobulinaemia, primary amyloidosis as well as monoclonal gammopathy of unknown significance (MGUS). The clinical manifestation is usually distal symmetric. Morphologically these polyneuropathies are demyelinating, intermediate or axonal with no difference between IgG- and IgM-MGUS. The differentiation between MGUS and chronic inflammatory demyelinating polyneuropathies (CIDP) may be difficult. An early correct diagnosis of polyneuropathy can help to discover myeloproliferative disorders (plasmocytoma, osteosclerotic myeloma). Furthermore, it is a prerequisite for successful treatment. Clinical neurophysiology plays an important role in the differential diagnosis of paraproteinaemic polyneuropathies.

Literatur

  • 1 Kyle R A, Therneau T M, Rajkumar S V. et al . A long-term study of prognosis in monoclonal gammopathy of undetermined significance.  New Engl J Med. 2002;  346 564-569
  • 2 Longo D L. Plasma cell disorders. In: Isselbacher KJ, Braunwald E, Wilson J, Martin JB, Fauci AS, Kasper DL (eds) Harrison's principles of internal medicine. New York; McGraw-Hill 1996: 1618-1625
  • 3 Eurelings M, Notermans N C, van de Donk N WCJ, Lokhorst H M. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.  Muscle & Nerve. 2001;  24 1295-1302
  • 4 Latov N. Prognosis of neuropathy with monoclonal gammopathy.  Muscle & Nerve. 2000;  23 150-152
  • 5 Wilson H C, Lunn M PT, Schey S, Hughes R AC. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.  J Neurol Neurosurg Psychiatry. 1999;  66 575-580
  • 6 Notermans N C, Franssen H, Eurelings M, Van der Graaf Y, Wokke J HJ. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy.  Muscle & Nerve. 2000;  23 73-79
  • 7 Maisonobe T, Chassande B, Vérin M, Jouni M, Léger J M, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.  J Neurol Neurosurg Psychiatry. 1996;  61 36-42
  • 8 Bromberg M B, Feldman E L, Albers J W. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy.  Neurology. 1992;  42 1157-1163
  • 9 Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, Manfredini E, Scarlato G. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies.  Acta Neurol Scand. 1992;  85 383-390
  • 10 Ponsford S, Willison H, Veitch J RM, Thomas P K. Long-term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated with benign monoclonal gammopathy.  Muscle & Nerve. 2000;  23 164-174
  • 11 Steck A J. Neurological manifestations of malignant and non-malignant dysglobulinaemias.  J Neurol. 1998;  245 634-639
  • 12 Suarez G A, Kelly J J. Polyneuropathy associated with monoclonal gammopathy of undetermined significance.  Neurology. 1993;  43 1304-1308
  • 13 Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies.  J Neurol Sci. 1993;  114 193-199
  • 14 Rudnicki S A, Harik S I, Dhodapkar M, Barlogie B, Eidelberg D. Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.  Neurology. 1998;  51 1210-1213
  • 15 Eureling M, Moons K GM, Notermans N C, Sasker L D. et al . Neuropathy and IgM M-proteins.  Neurology. 2001;  56 228-233
  • 16 Vedeler C, Ulvestad E, Nylend H, Matre R, Aarli J A. Receptors for gammaglobulin in the central and peripheral nervous system.  J Neurol Neurosurg Psychiatry. 1994;  57 (Suppl) 9-10
  • 17 Saperstein D S, Katz J S, Amato A A, Barohn R J. Clinical spectrum of chronic acquired demyelinating polyneuropathies.  Muscle & Nerve. 2001;  24 311-324
  • 18 Blume G, Pestronk A, Goodnough L T. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy wich monthly plasma exchange and IV cyclophosphamide.  Neurology. 1995;  45 1577-1580
  • 19 Murray N, Steck A J. Indication of a possible role in a demyelinating neuropathy for an antigen shared between myelin and NK cells.  The Lancet. 1984;  31 711
  • 20 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG igM M-proteins and its relationship to immune therapies.  Brain. 2000;  123 710-717
  • 21 Pestronk A, Li F, Bieser K, Choksi R, Whitton A, Kornberg A J, Goldstein J M, Yee W C. Anti-MAG antibodies: major effects of antigen purity and antibody crossreactivity on ELISA results and clinical correlation.  Neurology. 1994;  44 1131-1137
  • 22 Quarles R H, Weiss M D. Autoantibodies associated with peripheral neuropathy.  Muscle & Nerve. 1999;  22 800-822
  • 23 Willison H J, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies.  Brain. 2002;  125 2591-2625
  • 24 Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ (eds) Immunology and infectious diseases of the peripheral nerves. Cambridge; Cambridge University Press 1998: 168-189
  • 25 Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside.  Brain. 1994;  117 941-947
  • 26 Cocito D, Isoardo G, Ciaramitaro P. et al . Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody.  Muscle & Nerve. 2001;  24 1278-1282
  • 27 Galassi G, Nemni R. Sensory action potentials and biopsy of the sural nerve in the neuropathy of nonmalignant IgMk plasma cell dyscrasia.  Eur Neurol. 1986;  25 1-9
  • 28 Corbo M, Hays A P. Immunopathological studies in immune-mediated neuropathies. In: Latov N, Wokke JHJ, Kelly JJ (eds) Immunological and infectious diseases of the peripheral nerves. Cambridge; Cambridge University Press 1997: 81-95
  • 29 Kelly J J. Polyneuropathies associated with myeloma, POEMS, and non-malignant IgG and IgA monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ (eds) Immunology and infectious diseases of the peripheral nerves. Cambridge; Cambridge University Press 1998: 225-237
  • 30 Gorson K C, Ropper A H, Weinberg D H, Weinstein R. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy.  Arch Neurol. 2002;  59 766-772
  • 31 Sung J Y, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome.  Muscle & Nerve. 2002;  26 189-193
  • 32 Nakanishi T, Sobue I, Toyokara Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, Igara A, Ozaki Y. The Crow-Fukase syndrome: a study of 102 cases in Japan.  Neurology. 1984;  34q 712-720
  • 33 Claus D. Polyneuropathien bei Paraproteinämien und Amyloidosen. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik. Stuttgart; Thieme Verlag 1999: 423-430
  • 34 Brown W F. The physiological and technical basis of electromyography. Stoneham; Butterworth Publ 1984
  • 35 Brown W F, Feasby T E. Conduction block and denervation in Guillain-Barré polyneuropathy.  Brain. 1984;  107 219-239
  • 36 Claus D, Jaspert A, Grehl H, Neundörfer B. Immunvermittelte Polyneuropathien.  Dtsch Ärzteblatt. 1996;  93 B248-252
  • 37 Gold R, Dalakas M C, Toyka K V. Immunotherapy in autoimmune neuromuscular disorders.  Lancet. 2003;  2 22-32
  • 38 Dalakas M C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.  Muscle & Nerve. 1999;  22 1479-1497
  • 39 Mariette X, Chastang C, Clavelou P, Louboutin J P, Leger J M, Brouet J C. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropahty associated with monoclonal igM.  J Neurol Neurosurg Psychiatry. 1997;  63 28-34
  • 40 Comi G, Roveri L, Swan A, Willison H. et al . A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.  J Neurol. 2002;  249 1370-1377
  • 41 Gorson K C, Ropper A H, Weinberg D H, Weinstein R. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy.  Muscle & Nerve. 2001;  24 778-786
  • 42 Siciliano G, Moriconi L, Gianni G, Richieri E, Vignocchi M G, Rossi B. Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance.  Acta Neurol Scand. 1994;  89 117-122
  • 43 Reiners K, Hartung H P. Paraproteinämische Polyneuropathien.  Nervenheilkunde. 1996;  15 27-39
  • 44 Latov N, Wokke J HJ, Kelly J J. Immunology and infectious diseases of the peripheral nerves. Cambridge; Cambridge Univ. Press 1998
  • 45 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.  Neurology. 1999;  52 1701-1704
  • 46 Chaudhry V, Corse A M, Cornblath D R, Kuncl R W, Freimer M L, Griffin J W. Multifocal motor neuropathy: electrodiagnostic features.  Muscle & Nerve. 1994;  17 198-205
  • 47 Claus D. Conduction studies in proximal nerves.  Schweizer Archiv für Neurologie und Psychiatrie. 1991;  142 531
  • 48 Claus D. Motorisch evozierte Potenziale. In: Lowitzsch K, Hopf HC, Buchner H et al. (Hrsg) Das EP-Buch. Stuttgart; Thieme Verlag 2000: 173-232
  • 49 Lange D J, Trojaborg W, Latov N, Hays A P, Younger D S, Uncini A, Blake D M, Hirano M, Burns S M, Lovelace R E. et al . Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?.  Neurology. 1992;  42 497-505
  • 50 Neurology Am. Academy . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS task force.  Neurology. 1991;  41 617-618
  • 51 Wiles C M, Brown P, Chapel H, Guerri R. et al . Intravenous immunoglobulin in neurological disease: a specialist review.  J Neurol Neurosurg Psychiatry. 2002;  72 440-448

Prof. Dr. Detlef Claus

Klinik für Neurologie Klinische Neurophysiologie · Klinikum Darmstadt

Heidelberger Landstraße 379

64297 Darmstadt

Email: d.claus@t-online.de

    >